CD4 and malaria: In 2017, WHO published guidelines recommending cotrimoxazole prophylaxis to reduce morbidity and mortality among PLHIV whose CD4 count was ≤350 cells/mm3 or at clinical stage 3 or 4 or lifelong cotrimoxazole for any CD4 count in settings with a high prevalence of malaria or bacterial infections.